This important collaboration between Eccogene and AstraZeneca will accelerate the development of ECC5004, a once daily, low dose, orally available small molecule GLP-1RA to benefit the millions of patients worldwide living with these diseases." Sharon Barr, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said: "With the number of people living with cardiometabolic conditions and obesity today already over one billion, there is a need for continued innovation and next generation therapeutic options
GPX5 does not contain selenium cysteine (Secys) at its active site, but instead uses cysteine residues (Cys) as its active site
Sign up for a complimentary subscription to Digital Commerce 360 Retail News
Based on the federal notice and prior regulatory filings, the substances under consideration are drawn from the broader list of peptides that were placed on the Category 2 restricted list beginning in 2023
Supplement Facts: Serving Size: 1 Vegetable CapsuleAmount Per Serving%DVL-Glutathione (reduced) (Free Form)250 mg* *Daily Value (DV) not established Ingredients Microcrystalline Cellulose, Vegetable Cellulose, Vegetable Magnesium Stearate, Silica
